Severe AsthmaNCT07328035
Remission in Adults With Severe Asthma in Thailand
An observational study of Severe Asthma and Asthma Control Level, run by Thammasat University at 1 site in Thailand.
Trial summary
The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Severe Asthma, Asthma Control Level
- What is being tested?
- Spirometry, Fractional exhaled nitric oxide (FeNO) test and Blood eosinophil count (BEC)
- How many people
- 230 participants
- Where
- 1 siteThailand
- Study dates
- 1 Jan 2026to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Thai patients aged 18 years or older with severe asthma are included in the study
Who may be able to join
- severe asthma
- age 18 years or older
Who cannot join
- inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Thailand1 site, 1 recruiting
- Recruiting
Narongkorn Saiphoklang
Pathum Thani, 12120
Narongkorn Saiphoklang, MD, +6629269794, M_narongkorn@hotmail.com
Pacharaporn Tangsathapornpong, MD, +6629269701, pacharaporn.kaimook@gmail.com
About this study
The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.
Read the detailed description
This study is a cross-sectional study. Thai patients aged 18 years or older with severe asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
- Conditions
- Severe Asthma, Asthma Control Level
- Being tested
- Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires, Spirometry, Fractional exhaled nitric oxide (FeNO) test, Blood eosinophil count (BEC)
- Keywords
- asthma, remission, Thailand, severe, FeNO, blood eosinophil count
- Medical subject headings
- Asthma, Lymphoma, Follicular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnairesOther
GINA and ACT are questionnaires used to assess the level of asthma control.
SpirometryDiagnostic test
Spirometry is a tool used to assess pulmonary function.
Fractional exhaled nitric oxide (FeNO) testDiagnostic test
FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
Blood eosinophil count (BEC)Diagnostic test
BEC is a tool used to assess eosinophilic inflammation and asthma remission.
| Study group | Role | What they receive |
|---|---|---|
| Severe asthma | Asthma that requires treatment with high-dose inhaled corticosteroids plus a second controller, or requires systemic corticosteroids for ≥50% of the previous year to prevent it from becoming uncontrolled, or remains uncontrolled despite this therapy. Receives: Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires; Diagnostic Test: Spirometry; Diagnostic Test: Fractional exhaled nitric oxide (FeNO) test; Diagnostic Test: Blood eosinophil count (BEC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence rate of severe asthma remission
Prevalence rate of remission in adults with severe asthma
Measured: The beginning of the study
Secondary outcomes (3)
Association of clinical characteristics with severe asthma remission
The association between severe asthma remission and the following variables will be evaluated:
- Asthma symptom control; Asthma Control Test (ACT) score (range 5-25)
- Exacerbation history; Number of asthma exacerbations requiring systemic corticosteroids in the previous 12 months
- Oral corticosteroid use; Daily oral corticosteroid use (yes/no) and cumulative dose (mg/year)
- Asthma duration; Years since asthma diagnosis
Measured: The beginning of the study
Association of lung function with severe asthma remission
The association between severe asthma remission (binary outcome: remission vs. non-remission) and pulmonary function assessed using spirometry (FEV1 % predicted and FEV1/FVC ratio).
Measured: The beginning of the study
Association of inflammatory biomarkers with severe asthma remission
The association between severe asthma remission (binary outcome: remission vs. non-remission) and inflammatory biomarkers assessed using blood eosinophil count (cells/µL) and fractional exhaled nitric oxide (FeNO) (parts per billion, ppb).
Measured: The beginning of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2026
- Study start1 Jan 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Severe AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 230 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Thammasat University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Narongkorn Saiphoklang, MD, Thammasat University
- Investigators
- Narongkorn Saiphoklang, Principal investigator, Thammasat University Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07328035
- Sponsor's protocol ID
- MTU-EC-IM-0-283/68
- Status last verified
- Apr 2026
- First submitted
- 26 Dec 2025
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD and documents
Publications
McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
PubMed 37857423Tupper OD, Hakansson KEJ, Ulrik CS. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1595-1603.e5. doi: 10.1016/j.jaip.2020.11.013. Epub 2020 Nov 19.
PubMed 33220516Chipps BE, Lugogo N, Carr W, Zhou W, Patel A, Carstens DD, Trudo F, Ambrose CS. On-treatment clinical remission of severe asthma with real-world longer-term biologic use. J Allergy Clin Immunol Glob. 2024 Oct 30;4(1):100365. doi: 10.1016/j.jacig.2024.100365. eCollection 2025 Feb.
PubMed 39659738Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fageras M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimaki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taille C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bulow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC.
PubMed 38701495Hansen S, Baastrup Sondergaard M, von Bulow A, Bjerrum AS, Schmid J, Rasmussen LM, Johnsen CR, Ingebrigtsen T, Hakansson KEJ, Johansson SL, Bisgaard M, Assing KD, Hilberg O, Ulrik C, Porsbjerg C. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies. Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
PubMed 37925144Holm M, Omenaas E, Gislason T, Svanes C, Jogi R, Norrman E, Janson C, Toren K; RHINE Study Group. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62-5. doi: 10.1183/09031936.00121705. Epub 2007 Mar 14.
PubMed 17360725Almqvist L, Ronmark E, Stridsman C, Backman H, Lindberg A, Lundback B, Hedman L. Remission of adult-onset asthma is rare: a 15-year follow-up study. ERJ Open Res. 2020 Nov 23;6(4):00620-2020. doi: 10.1183/23120541.00620-2020. eCollection 2020 Oct.
PubMed 33263024
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Remission in Adults With Severe Asthma in Thailand
- ClinicalTrials.gov ID
- NCT07328035
- Acronym / sponsor ID
- MTU-EC-IM-0-283/68
- Conditions
- Severe Asthma, Asthma Control Level
- Keywords
- asthma, remission, Thailand, severe, FeNO, blood eosinophil count
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 230 participants (estimated)
- Lead sponsor
- Thammasat UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 8 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.
Detailed description
This study is a cross-sectional study. Thai patients aged 18 years or older with severe asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Severe asthma | – | Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires, Diagnostic Test: Spirometry, Diagnostic Test: Fractional exhaled nitric oxide (FeNO) test, Diagnostic Test: Blood eosinophil count (BEC)Asthma that requires treatment with high-dose inhaled corticosteroids plus a second controller, or requires systemic corticosteroids for ≥50% of the previous year to prevent it from becoming uncontrolled, or remains uncontrolled despite this therapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Thai patients aged 18 years or older with severe asthma are included in the study
Key inclusion criteria (2 listed)
- severe asthma
- age 18 years or older
Key exclusion criteria (1 listed)
- inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnairesGINA and ACT are questionnaires used to assess the level of asthma control. | Other | Severe asthma |
| SpirometrySpirometry is a tool used to assess pulmonary function. | Diagnostic test | Severe asthma |
| Fractional exhaled nitric oxide (FeNO) testFeNO is a tool used to assess eosinophilic airway inflammation and asthma remission. | Diagnostic test | Severe asthma |
| Blood eosinophil count (BEC)BEC is a tool used to assess eosinophilic inflammation and asthma remission. | Diagnostic test | Severe asthma |
Primary outcome
Prevalence rate of severe asthma remission
Time frame: The beginning of the study
Prevalence rate of remission in adults with severe asthma
3 secondary outcomes
Association of clinical characteristics with severe asthma remission
Time frame: The beginning of the study
Association of lung function with severe asthma remission
Time frame: The beginning of the study
Association of inflammatory biomarkers with severe asthma remission
Time frame: The beginning of the study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
- Results publication: PubMed 37857423McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
- Results publication: PubMed 33220516Tupper OD, Hakansson KEJ, Ulrik CS. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1595-1603.e5. doi: 10.1016/j.jaip.2020.11.013. Epub 2020 Nov 19.
- Results publication: PubMed 39659738Chipps BE, Lugogo N, Carr W, Zhou W, Patel A, Carstens DD, Trudo F, Ambrose CS. On-treatment clinical remission of severe asthma with real-world longer-term biologic use. J Allergy Clin Immunol Glob. 2024 Oct 30;4(1):100365. doi: 10.1016/j.jacig.2024.100365. eCollection 2025 Feb.
- Results publication: PubMed 38701495Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fageras M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimaki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taille C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bulow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC.
- Results publication: PubMed 37925144Hansen S, Baastrup Sondergaard M, von Bulow A, Bjerrum AS, Schmid J, Rasmussen LM, Johnsen CR, Ingebrigtsen T, Hakansson KEJ, Johansson SL, Bisgaard M, Assing KD, Hilberg O, Ulrik C, Porsbjerg C. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies. Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
- Results publication: PubMed 17360725Holm M, Omenaas E, Gislason T, Svanes C, Jogi R, Norrman E, Janson C, Toren K; RHINE Study Group. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62-5. doi: 10.1183/09031936.00121705. Epub 2007 Mar 14.
- Results publication: PubMed 33263024Almqvist L, Ronmark E, Stridsman C, Backman H, Lindberg A, Lundback B, Hedman L. Remission of adult-onset asthma is rare: a 15-year follow-up study. ERJ Open Res. 2020 Nov 23;6(4):00620-2020. doi: 10.1183/23120541.00620-2020. eCollection 2020 Oct.
- Individual participant dataSharing planned: Yes. IPD and documents
Related trials for Severe Asthma
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
RecruitingPhase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma
Asthma
RecruitingPhase 3
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Severe Asthma
Active, not recruitingPhase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Narongkorn Saiphoklang principal investigator
Thammasat University Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Severe Asthma and Asthma Control Level, run by Thammasat University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Narongkorn Saiphoklang, MD (+6629269794, M_narongkorn@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence rate of severe asthma remission (time frame: The beginning of the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07328035, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.